Effect of Vascular Endothelial Growth Factor Inhibition on Endometrial Implant Development in a Murine Model of Endometriosis

Analía Gabriela Ricci, Carla Noemí Olivares, Mariela Andrea Bilotas, Mariela Bilotas, Gabriela Meresman, Gabriela Fabiana Meresman, Rosa Inés Barañao
Reproductive sciences (Thousand Oaks, Calif.) · 2011 · vol. 18(7) , pp. 614–622 · doi:10.1177/1933719110395406 · PMID:21266664 · W2169855351
article OA: bronze CC0 ⤵ 89 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

Bevacizumab treatment significantly inhibited endometriotic lesion development by reducing cell proliferation, vascular density, and increasing apoptosis while lowering VEGF levels in peritoneal fluid.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 ⓘ

This paper investigated whether inhibiting vascular endothelial growth factor (VEGF) activity with the anti-VEGF monoclonal antibody bevacizumab affects ectopic endometrial implant development in a murine model of endometriosis. Two-month-old female BALB/c mice received surgery to induce endometriotic-like lesions, then were treated with bevacizumab starting on post-surgery day 15 for 2 weeks; lesions were quantified after sacrifice and lesion biology assessed via immunohistochemistry (PCNA for proliferation, CD34 for vascular density, and TUNEL for apoptosis), alongside VEGF measurement in peritoneal fluid by ELISA. Bevacizumab significantly reduced endometriotic-like lesion development, decreased cell proliferation, reduced vascular density, increased apoptotic cell percentages, and lowered peritoneal fluid VEGF levels. The study’s key limitation is that it uses a mouse model with induced lesions rather than directly testing mechanisms in human disease. This paper is centrally about endometriosis — it tests VEGF inhibition (bevacizumab) on endometrial implant development in a murine endometriosis model.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Angiogenesis Inhibitors Antibodies, Monoclonal Endometriosis Endometriosis Vascular Endothelial Growth Factor A Angiogenesis Inhibitors Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antigens, CD34 Ascitic Fluid Ascitic Fluid Ascitic Fluid Bevacizumab Cell Proliferation Cell Proliferation Disease Models, Animal Endometriosis Female In Situ Nick-End Labeling

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (46)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:54.825375+00:00
License: CC0 · commercial use OK